<DOC>
	<DOCNO>NCT01626092</DOCNO>
	<brief_summary>This study design test ability achieve donor hematopoietic engraftment maintain low rate transplant-related mortality ( TRM ) patient high-risk lysosomal peroxisomal disorder use novel condition regimen hematopoietic cell transplantation ( HCT ) . After reduced-intensity conditioning regimen use volumetric-modulated arc therapy ( VMAT ) -delivered low-dose total body irradiation ( TBI ) highly conformal marrow boosting , patient transplant use either relate unrelated allograft . The cell source may marrow , peripheral blood cord blood base donor availability .</brief_summary>
	<brief_title>Reduced-Intensity Hematopoietic Stem Cell Transplant High Risk Lysosomal Peroxisomal Disorders</brief_title>
	<detailed_description>The condition regimen consist alemtuzumab ( Campath-1H ) , clofarabine , melphalan , VMAT-delivered low-dose TBI boost marrow irradiation . Additional graft-versus-host disease prophylaxis consist mycophenolate mofetil cyclosporine .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Lysosomal Storage Diseases</mesh_term>
	<mesh_term>Peroxisomal Disorders</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Adrenoleukodystrophy ( ALD ) : Patients 055 year age diagnose ALD determine long chain fatty acid test eligible protocol evidence cerebral cerebellar disease base MRI test , Metachromatic Leukodystrophy ( MLD ) : Patients 055 year age diagnose MLD determine arylsulfatase A activity . Globoid Cell Leukodystrophy ( GLD ) : Patients 055 year age diagnose GLD determine galactocerebrosidase activity eligible protocol Wolman 's disease , GM1 gangliosidosis , Tay Sachs disease , Sanfilippo syndrome , Sandhoff disease inherit metabolic disease include limited Icell disease ( mucolipidosis II ) : Patients determine sufficiently advance high risk base follow reason : Symptomatic disease , base neurologic examination evidence deterioration base subsequent neuropsychologic evaluation . Evidence expect poor outcome base genetic test prior family history aggressive disease . Other metabolic disorder , include limit Icell disease , deem highrisk poor outcome standard transplant regimen due anticipate toxicity base experience gain University Minnesota center . Donor Availability Transplantation use sufficiently match related donor ( matched sibling ) unrelated donor consider . Both granulocytecolony stimulating factor ( GCSF ) stimulate peripheral blood graft bone marrow graft consider , although bone marrow priority . Cord blood graft , relate unrelated , also eligible . As protocol use reduce intensity regimen , protocol use current recommendation University Minnesota choose cord blood graft . If single cord blood unit cell dose insufficient , double cord transplantation consider sufficiently match cord blood unit available . The priority choose cord blood donor base current institutional recommendation . Exclusion Metabolic Disorder Carrier Status relate donor unrelated cord blood graft appropriate primary disease . Adequate Organ Function Measured within 30 day study enrollment Signed consent Inability receive total body irradiation ( TBI ) marrow boost per protocol guideline determine Radiation Oncologist Pregnant Menstruating female must negative serum pregnancy test within 14 day treatment start . Advanced Disease Exclusion : Following evaluation , consensus member Inherited Metabolic Storage Disease Program patient advance benefit measurable meaningful way transplant , communicate family , transplant offer .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>bone marrow transplantation</keyword>
	<keyword>reduce intensity conditioning</keyword>
	<keyword>Adrenoleukodystrophy</keyword>
	<keyword>Metachromatic Leukodystrophy</keyword>
	<keyword>Globoid Cell Leukodystrophy</keyword>
	<keyword>Wolman 's disease</keyword>
	<keyword>GM1 gangliosidosis</keyword>
	<keyword>Tay Sachs disease</keyword>
	<keyword>Sanfilippo syndrome</keyword>
	<keyword>Sandhoff disease</keyword>
	<keyword>inherit metabolic</keyword>
	<keyword>I-cell disease</keyword>
	<keyword>mucolipidosis II</keyword>
</DOC>